GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GlaxoSmithKline (GSK) has recently completed a Phase 2b clinical study titled ‘A Phase 2b, Randomized, Controlled, Open-label Study to Evaluate the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults (>=18 Years of Age) When Administered to Lung and Renal Transplant Recipients Comparing 1 Versus 2 Doses and Compared to Healthy Controls (>=50 Years of Age)’. The study aimed to assess the immune response and safety of the RSVPreF3 OA vaccine in immunocompromised adults who have received lung or kidney transplants, as well as in healthy adults aged 50 and above. This research is significant as it explores the potential of the vaccine to enhance immune response in vulnerable populations.
The intervention tested was the RSVPreF3 OA Investigational Vaccine, a biological treatment intended to prevent respiratory syncytial virus (RSV) infections. The vaccine was administered intramuscularly in either one or two doses, depending on the participant group.
The study was interventional, with a randomized allocation and a parallel intervention model. It was open-label, meaning no masking was used, and its primary purpose was prevention. The study compared different dosing regimens in transplant recipients and healthy adults.
The study began on July 28, 2023, with primary completion expected by June 25, 2025, and the last update submitted on August 6, 2025. These dates are crucial as they mark the progress and timeline for potential market entry.
The completion of this study could have positive implications for GSK’s stock performance, as successful results might boost investor confidence and position GSK favorably in the competitive vaccine market. With the ongoing focus on vaccine development, GSK’s advancements in RSV prevention could enhance its market standing.
The study is ongoing, and further details are available on the ClinicalTrials portal.